Back to Search
Start Over
Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.
- Source :
-
Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2014 Apr; Vol. 28 (2), pp. 375-86. Date of Electronic Publication: 2014 Jan 18. - Publication Year :
- 2014
-
Abstract
- Use of new compound such as inhibitors of JAK2 or transforming growth factor β-like molecules might soon revolutionize the treatment of β-thalassemia and related disorders. However, this situation requires careful optimization, noting the potential for off-target immune suppression for JAK2 inhibitors and the lack of mechanistic insights for the use of the ligand trap soluble molecules that sequester ligands of activin receptor IIA and B.<br /> (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Subjects :
- Activin Receptors, Type II antagonists & inhibitors
Activin Receptors, Type II metabolism
Erythrocytes drug effects
Erythrocytes metabolism
Erythropoiesis drug effects
Hemoglobinopathies drug therapy
Hemoglobinopathies metabolism
Humans
Janus Kinase 2 antagonists & inhibitors
Janus Kinase 2 metabolism
Molecular Targeted Therapy methods
Molecular Targeted Therapy trends
Recombinant Fusion Proteins pharmacology
Recombinant Fusion Proteins therapeutic use
beta-Thalassemia drug therapy
beta-Thalassemia metabolism
Erythrocytes physiology
Erythropoiesis physiology
Hemoglobinopathies physiopathology
beta-Thalassemia physiopathology
Subjects
Details
- Language :
- English
- ISSN :
- 1558-1977
- Volume :
- 28
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Hematology/oncology clinics of North America
- Publication Type :
- Academic Journal
- Accession number :
- 24589272
- Full Text :
- https://doi.org/10.1016/j.hoc.2013.12.001